ABSTRACT
ObjectiveTo evaluate the association between exposure to environmental levels of PM2.5 and mortality from SARS-CoV-2 in inhabitants of Mexico City. Material and methodsA secondary analysis with the total number of deaths from COVID-19 in residents of Mexico City as well as 25 municipalities in the interior of the Republic was carried out. Environmental levels of PM2.5 were between 2018 and 2021. Bivariate analysis and multivariate logistic regression were performed. ResultsA total of 1,083,175 cases of COVID-19 were included, with 57,384 deaths (5.3%), of which 30,561 were in residents with exposure to more than 20 g/m3 of PM2.5 (OR 1.27, CI95%: 1.25 to 1.29). When performing the multivariate analysis, an OR of 1.39 (CI95%: 1.36 to 1.43) was observed. ConclusionsChronic exposure to elevated levels of PM2.5 is associated with increased death risk from COVID-19.
ABSTRACT
To determine the efficacy and safety of fixed combination of hydroxychloroquine/azithromycin (HCQ+AZT) compared to hydroxychloroquine (HCQ) alone or placebo in mild COVID-19 outpatients to avoid hospitalization. Materials and methodsThis randomized, parallel, double-blind clinical trial included male and female patients aged 18 and 76 years non COVID vaccinated, who were diagnosed with mild COVID-19 infection. All patients underwent liver and kidney profile test, as well as a health questionnaire and clinical revision to document that they did not have uncontrolled comorbidities. They were randomly assigned to one of the three treatment arms: 1) hydroxychloroquine with azithromycin 200 mg/250 mg every 12 hours for five days followed by hydroxychloroquine 200 mg every 12 hours for 5 days; 2) hydroxychloroquine 200 mg every 12 hours for ten days; or 3) placebo every 12 hours for ten days. The primary outcome of the study was hospitalization, while the secondary outcomes were disease progression, pneumonia, use of supplemental oxygen, and adverse events. This study was registered in clinicaltrials.gov with the NCT number of 04964583. ResultsA total of 92 participants were randomized. Of whom, 30 received HCQ+AZT, 31 received HCQ, and 31 received placebo. The median age was 37 years, 27.2% of the participants had comorbidities, and the global incidence of hospitalization was 2.2%. The incidence of hospitalization was 6.7% (2/30) in the HCQ+AZT group compared to the HCQ or placebo groups, in which there were no hospitalizations. Progression of disease was higher in the HCQ group [RR=3.25 (95% CI, 1.19-8.87)] compared with placebo group. There was no statistical difference between the HCQ+AZT group and the placebo group in progression of disease. The incidence of pneumonia was 30% in the HCQ+AZT group, 32.2% in the HCQ group, and 9.6% in the placebo group (HCQ + AZT vs Placebo; p=0.06). There was a significant risk of pneumonia versus placebo only in the HCQ group [RR=3.33 (95% CI, 1.01-10.9)]. Supplemental oxygen was required by 20% (6/30) of the patients in the HCQ+AZT group, 6.4 (2/31) of the patients in the HCQ group, and 3.2% (1/31) of the patients in the placebo group,[(HCQ + AZT vs Placebo; p=0.100), (HCQ vs Placebo, p=0.610)]. There was no statistical difference between groups for negative test (PCR) on day 11. The most frequent adverse events were gastrointestinal symptoms. No lengthening of the QT interval was observed in patients receiving HCQ+AZT or HCQ. ConclusionThe use of HCQ+AZT does not decrease the risk of hospitalization in patients with mild COVID-19. The use of HCQ increases the risk of progression and pneumonia.
ABSTRACT
The aim of this study was to evaluate bone quality and nutritional status in children with congenital heart defects (CHDs) using quantitative ultrasound. A cross-sectional study was designed. A population-based sample of 75 children with CHD (age: 0--6yr) from the Department of Pediatric Cardiology at the National Cardiology Institute "Ignacio Chávez" was compared with 106 healthy children during 2009. Weight and height were determined in both groups; bone status was measured at the radius and tibia as speed of sound (SOS). Nutritional status was defined according to the Waterloo and Gómez index. Chi-square test, Student's t-test, and analysis of variance were used to determine the statistical differences. A linear regression analysis adjusted by age, weight, height, type of CHD, and birth weight was made. Both groups were similar in sex distribution, prematurity, and birth weight. Acyanotic cardiopathy with increased pulmonary flow was the most frequent (61.3%). Prevalence of malnutrition was higher in CHD group compared with healthy children (p<0.001), and radius SOS was lower in children with CHD compared with healthy children (3484±180 vs 3575±159m/s, respectively; 95% confidence interval: 39.8--143; p=0.001). A positive correlation was found between CHD and reduced SOS in the adjusted linear regression model, r²=0.455 (p<0.001). Children with CHD have lower SOS radius values compared with healthy children, suggesting reduced bone quality regardless of the nutritional status.
